GSK boosts growth with oncology pipeline expansion and £1.9B cost savings reinvested in drug development

GSK is expanding its oncology drug pipeline through acquisitions and promising clinical trial results, including a 94% response rate for its lung cancer drug Jideytro. The company plans to save nearly £1.90 billion in costs, reinvesting these funds to accelerate drug development and offset patent expirations. Analysts see nearly 20% upside potential, reflecting confidence in GSK's strategic growth and innovation efforts.

As of Sep 15, 2026 20:48 WIB, GSK shares are trading at USD 49.65 on Pluang, down 0.80% for the day. The company holds a market capitalization of $100.50 billion and offers a dividend yield of 3.63%. This pricing context highlights investor response amid GSK's focus on oncology growth and cost savings strategies.